Literature DB >> 8044939

Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli.

I M Lang1, J J Marsh, M A Olman, K M Moser, R R Schleef.   

Abstract

BACKGROUND: Chronic thromboembolic pulmonary hypertension is the result of nonresolving pulmonary emboli that lead to chronic obstruction of the central pulmonary arteries. METHODS AND
RESULTS: To determine if the failure to lyse pulmonary thromboemboli is caused by an abnormality in the endothelial cell (EC)-associated fibrinolytic system, conditions were established to culture ECs from patient main pulmonary arteries during surgical pulmonary thromboendarterectomies and to analyze the conditioned media for levels of tissue-type plasminogen activator (TPA) and type 1 plasminogen activator inhibitor (PAI-1). Our data indicate that the levels of TPA antigen and PAI-1 activity in media conditioned by primary ECs harvested from areas free of thrombus were not significantly different between patients with chronic thromboemboli and organ donors. In 13 consecutive patients, no correlation was obtained in either the TPA antigen or PAI-1 activity level in a patient's plasma and the respective levels in media conditioned by the patient's pulmonary ECs. Moreover, patient pulmonary arterial ECs were observed to increase the secretion of TPA and PAI-1 in response to thrombin in a fashion similar to donor pulmonary artery ECs.
CONCLUSIONS: The data suggest that an inherent EC-mediated fibrinolytic imbalance is not a generalized phenomenon observed in pulmonary arteries of patients with chronic pulmonary thromboemboli.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8044939     DOI: 10.1161/01.cir.90.2.706

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

Review 1.  Chronic thromboembolic pulmonary hypertension (CTEPH).

Authors:  Keith McNeil; John Dunning
Journal:  Heart       Date:  2007-09       Impact factor: 5.994

2.  Splenectomy and chronic thromboembolic pulmonary hypertension.

Authors:  X Jaïs; V Ioos; C Jardim; O Sitbon; F Parent; A Hamid; E Fadel; P Dartevelle; G Simonneau; M Humbert
Journal:  Thorax       Date:  2005-08-05       Impact factor: 9.139

3.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

Review 4.  AngioVac for Minimally Invasive Removal of Intravascular and Intracardiac Masses: a Systematic Review.

Authors:  Tariq Enezate; Deya Alkhatib; Joel Raja; Viswanatha Chinta; Mitul Patel; Jad Omran
Journal:  Curr Cardiol Rep       Date:  2022-02-07       Impact factor: 2.931

5.  Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis.

Authors:  Timothy A Morris; James J Marsh; Peter G Chiles; William R Auger; Peter F Fedullo; Virgil L Woods
Journal:  Am J Respir Crit Care Med       Date:  2006-03-02       Impact factor: 21.405

Review 6.  Coagulation and the vessel wall in pulmonary embolism.

Authors:  Sherin Alias; Irene M Lang
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

7.  Increased expression and activity of sodium channels in alveolar type II cells of hyperoxic rats.

Authors:  G Yue; W J Russell; D J Benos; R M Jackson; M A Olman; S Matalon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

8.  Chronic exposure to fibrin and fibrinogen differentially regulates intracellular Ca2+ in human pulmonary arterial smooth muscle and endothelial cells.

Authors:  Amy L Firth; Jocelyn Yau; Amanda White; Peter G Chiles; James J Marsh; Timothy A Morris; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-04-10       Impact factor: 5.464

Review 9.  Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension.

Authors:  Daniel T Matthews; Anna R Hemnes
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

10.  Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury.

Authors:  Anil Sapru; Martha A Q Curley; Sandra Brady; Michael A Matthay; Heidi Flori
Journal:  Intensive Care Med       Date:  2009-10-24       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.